Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant

Allogeneic transplant remains the best postremission therapy for patients with nonfavorable risk acute myeloid leukemia (AML). However, some patients are ineligible because of psychosocial barriers, such as lack of appropriate caregiver support. We hypothesized that immune checkpoint inhibition afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomon, Scott R., Solh, Melhem, Morris, Lawrence E., Holland, H. Kent, Bachier-Rodriguez, Lizamarie, Zhang, Xu, Guzowski, Caitlin, Jackson, Katelin C, Brown, Stacey, Bashey, Asad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500475/
https://www.ncbi.nlm.nih.gov/pubmed/37379271
http://dx.doi.org/10.1182/bloodadvances.2023010477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500475/
https://www.ncbi.nlm.nih.gov/pubmed/37379271
http://dx.doi.org/10.1182/bloodadvances.2023010477

Ejemplares similares